Ipratropium bromide, Fenoterol

The dose should be selected individually. Unless otherwise instructed by the physician, the following doses are recommended: Adults and children over 6 years of age: Treatment of seizures In most cases, two inhaled aerosols are enough to relieve symptoms. If within 5 minutes of relief breathing has not come, you can use an additional 2 inhalation doses. If there is no effect after 4 inhalation doses and additional inhalations are required, you should immediately seek medical attention. Intermittent and long-term therapy: 1-2 inhalations per dose, up to 8 inhalations per day (an average of 1-2 inhalations 3 times a day). In bronchial asthma, the drug should be used only as needed. Ipraterol-aeronaut should be used in children only by prescription and under the supervision of adults (see the section "Special Instructions").

Existing clinical experience has shown that fenoterol and ipratropium bromide do not have a negative effect on pregnancy. However, when using these drugs during pregnancy (second and third trimester), normal precautions should be observed. It is necessary to take into account the inhibitory effect of the drug Ipraterol-aeronaut on uterine contractility. Fenoterol passes into breast milk. With regard to ipratropium bromide, such data are not obtained. The safety of the drug during lactation has not been established. In this regard, the use of the drug Ipraterol-aeronaut during lactation is possible only in cases where the potential benefit to the mother outweighs the potential risk to the child.

In the case of an unexpected rapid increase in shortness of breath (difficulty breathing), you should immediately consult a doctor. In children, the drug should be used only on prescription and under the supervision of adults.

Use in children under 6 years of age is contraindicated due to lack of experience with the application. Hypersensitivity: Immediately after the use of the drug Ipraterol, an immediate hypersensitivity reaction may occur, signs in which in rare cases can be: urticaria, angioedema, rash, bronchospasm, oropharynx edema, anaphylactic shock. Paradoxical bronchospasm: Ipraterol-aeronaut, like other inhalation drugs, can cause paradoxical bronchospasm, which can be life-threatening. In the case of the development of paradoxical bronchospasm, the use of the drug Ipraterol-aeronaut should be immediately stopped and switched to alternative therapy.

Prolonged use: - In patients suffering from bronchial asthma, Ipraterol-aeronaut should be used only as needed.

In patients with a mild form of chronic obstructive pulmonary disease, symptomatic treatment may be preferable to regular use; - in patients with bronchial asthma should be aware of the need for or enhance anti-inflammatory therapy to control the inflammatory process of the respiratory tract and the course of the disease. Regular use of increasing doses of drugs containing β2-adrenomimetics, such as the drug Ipraterol-aeronaut, to relieve bronchial obstruction can cause an uncontrolled worsening of the course of the disease. In the case of increased bronchial obstruction, an increase in the dose of β2-adrenomimetics, including the drug Ipraterol-aeronativ, more than recommended for a long time is not only not justified, but also dangerous.To prevent a life-threatening deterioration in the course of the disease, consideration should be given to revising the patient's treatment plan and adequate anti-inflammatory therapy with inhaled glucocorticosteroids. Other sympathomimetic bronchodilators should be prescribed simultaneously with the drug Ipraterol-aeronaut only under medical supervision. Disorders of the gastrointestinal tract: In patients with a history of cystic fibrosis, violations of motility of the gastrointestinal tract are possible.

Violations on the part of the organ of vision: Ipraterol-aeronaut should be used with caution in patients predisposed to angle-closure glaucoma. There are separate reports of complications from the organ of vision (for example, increased intraocular pressure, mydriasis, angle-closure glaucoma, pain in the eyes) that developed when inhaled ipratropium bromide (or ipratropium bromide in combination with β2-adrenomimetics) in the eye. Symptoms of acute angle-closure glaucoma can be pain or discomfort in the eyes, blurred vision, the appearance of a halo around objects and colored spots before the eyes, combined with corneal edema and reddening of the eye, due to conjunctival hyperemia. If any combination of these symptoms develops, the use of eye drops, reducing intraocular pressure, and an immediate consultation with a specialist are indicated. Patients should be instructed on the correct use of the inhalation drug Ipraterol-aeronaut. Particular care should be taken to protect the eyes of patients prone to the development of glaucoma. Systemic effects: In diseases such as recent myocardial infarction (during the last 3 months), inadequately controlled diabetes mellitus, serious organic diseases of the heart and blood vessels, hyperthyroidism, pheochromocytoma, or urinary obstruction (for example, prostatic hyperplasia or cervical obstruction) bladder) Ipraterol-aeronaut should be applied only after a thorough assessment of the risk / benefit. Effect on the cardiovascular system: In postmarketing studies, there have been rare cases of myocardial ischemia when taking β2-adrenomimetics. Patients with concomitant serious heart disease (for example, ischemic heart disease, arrhythmias, or severe heart failure) who are receiving Ipraterol-Aeronaut should be warned about the need to see a doctor if they develop heart pain or other symptoms that indicate worsening heart disease. It is necessary to pay attention to symptoms such as shortness of breath and chest pain, as they can be of both heart and lung etiology.

Hypokalemia: When using β2-adrenomimetics, hypokalemia may occur (see the “Overdose” section). In athletes, the use of the drug Ipraterol-aeronaut due to the presence of fenoterol in its composition can lead to positive results of tests for doping. Impact on the ability to drive a car and other vehicles, to work with moving mechanisms There have been no studies on the effect of the drug on the ability to drive vehicles and control mechanisms. In the event of such adverse reactions as dizziness, tremor, disturbance of accommodation, mydriasis and blurred vision, one should refrain from driving vehicles and controlling mechanisms, as well as from engaging in other potentially hazardous activities that require increased concentration and psychomotor reactions.

Symptoms Overdose symptoms are associated primarily with the effect of fenoterol. Symptoms may appear due to excessive stimulation of β-adrenoreceptors.The most likely occurrence of tachycardia, palpitations, tremors, hypertension or hypotension, increasing the difference between systolic and diastolic blood pressure, angina, arrhythmias and feelings of blood flow to the face, hyperglycemia, metabolic acidosis, hypokalemia. The possible symptoms of ipratropium bromide overdose (such as dry mouth, disturbed accommodation), given the greater breadth of the therapeutic effect of the drug and the local route of administration, are usually mild and transient. Treatment It is necessary to stop taking the drug. Blood pressure monitoring data should be taken into account. Showing sedatives, tranquilizers, in severe cases - intensive therapy. As a specific antidote, it is possible to use β-blockers, preferably β1-selective blockers. However, you should be aware of the possible increase in bronchial obstruction under the influence of β-blockers and carefully select the dose for patients suffering from bronchial asthma or chronic obstructive pulmonary disease, due to the risk of severe bronchospasm, which can be fatal.